Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
Sentivera, a biotech backed by Metsera investors, has been founded with a $1.5 billion deal to develop an inflammatory disease treatment. The company has obtained an exclusive license agreement from China's Haisco for a pre-clinical drug. This deal is Haisco's second major partnership this year, worth up to $1.5 billion-plus. Sentivera aims to advance the development of this immunology asset.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Sentivera was founded by backers of Metsera.
- ✓ The deal with Haisco is worth up to $1.5 billion.
- ✓ Haisco has partnered with US venture capital firms ARCH Venture Partners and Population Health Partners.
- ✓ The partnership involves an exclusive license agreement for a pre-clinical immunology asset.
What changed
The emergence of Sentivera as a new biotech company with a significant deal
Live updates
-
Sentivera emerges with $1.5B inflammatory disease deal
Sentivera, a biotech backed by Metsera investors, has been founded with a $1.5 billion deal to develop an inflammatory disease treatment. The company has obtained an exclusive license agreement from China's Haisco for a pre-clinical drug. This deal is Haisco's second major partnership this year, worth up to $1.5 billion-plus. Sentivera aims to advance the development of this immunology asset.
Why it matters
The deal highlights the growing interest in immunology and inflammatory disease treatments. Haisco, a Chinese company, is partnering with US venture capital firms, including ARCH Venture Partners and Population Health Partners. This collaboration brings together resources and expertise to accelerate the development of new treatments.
What is confirmed
- Sentivera was founded by backers of Metsera.
- The deal with Haisco is worth up to $1.5 billion.
- Haisco has partnered with US venture capital firms ARCH Venture Partners and Population Health Partners.
- The partnership involves an exclusive license agreement for a pre-clinical immunology asset.
What to watch next
- Progress in clinical trials for the licensed drug
- Further investments in Sentivera
- Regulatory decisions on the pre-clinical drug
confidence 90%Sources used for this update (7)
- Fierce Biotech — Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
- BioSpace — China’s Haisco forms immunology biotech with up to $1.5B from American VCs
- Endpoints News — ARCH and Population Health join China blitz with Haisco deal
- TradingView — Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners
- Investing.com — Haisco licenses pre-clinical drug to US venture for $1.5 billion
- Pharmaceutical Technology — Metsera backers establish new biotech armed with China-licensed immunology asset
- insights.citeline.com — Haisco Inks Second Deal This Year With A Startup, Worth Up To $1.5bn-Plus
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community